{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:09:20Z","timestamp":1787504960522,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10067-025-07858-2","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T21:33:32Z","timestamp":1765316012000},"page":"1395-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of ischemic stroke in benzbromarone versus allopurinol users: a real-world cohort study using TriNetX"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7420-1572","authenticated-orcid":false,"given":"Shih-Wei","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Fu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"7858_CR1","doi-asserted-by":"publisher","unstructured":"GBD 2019 Stroke Collaborators (2021) Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: A systematic analysis for the global burden of disease study 2019. Lancet Neurol 20(10):795\u2013820. https:\/\/doi.org\/10.1016\/S1474-4422(21)00252-0","DOI":"10.1016\/S1474-4422(21)00252-0"},{"key":"7858_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(20)31179-X","volume":"396","author":"BCV Campbell","year":"2020","unstructured":"Campbell BCV, Khatri P (2020) Stroke. Lancet. 396:129\u201342","journal-title":"Stroke. Lancet."},{"key":"7858_CR3","doi-asserted-by":"crossref","unstructured":"Kuwabara M, Hisatome I, Ae R, Kosami K, Aoki Y, Andres-Hernando A et al (2025) Hyperuricemia, A new cardiovascular risk. Nutr Metab Cardiovasc Dis. 35:103796","DOI":"10.1016\/j.numecd.2024.103796"},{"key":"7858_CR4","doi-asserted-by":"crossref","unstructured":"Padda J, Khalid K, Padda S, Boddeti NL, Malhi BS, Nepal R et al (2021) Hyperuricemia and its association with ischemic stroke.Cureus 13:e18172","DOI":"10.7759\/cureus.18172"},{"key":"7858_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.18071\/isz.71.0279","volume":"71","author":"T Acar","year":"2018","unstructured":"Acar T, G\u00fczey Aras Y, G\u00fcl SS, Acar AB (2018) Can high uric acid levels be an independent risk factor for acute ischemic stroke due to large-artery atherosclerosis? Ideggyogy Sz 71:279\u201383","journal-title":"Ideggyogy Sz"},{"key":"7858_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/heartjnl-2012-302535","volume":"99","author":"M Kanbay","year":"2013","unstructured":"Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ (2013) The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 99:759\u201366","journal-title":"Heart"},{"key":"7858_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/HYPERTENSIONAHA.115.06531","volume":"67","author":"C Borghi","year":"2016","unstructured":"Borghi C, Desideri G (2016) Urate-lowering drugs and prevention of cardiovascular disease: the emerging role of xanthine oxidase inhibition. Hypertension 67:496\u20138","journal-title":"Hypertension"},{"key":"7858_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12883-016-0692-2","volume":"16","author":"JA Singh","year":"2016","unstructured":"Singh JA, Yu S (2016) Allopurinol and the risk of stroke in older adults receiving medicare. BMC Neurol 16:164","journal-title":"BMC Neurol"},{"key":"7858_CR9","doi-asserted-by":"crossref","unstructured":"van der Pol KH, Wever KE, Verbakel M, Visseren FLJ, Cornel JH,Rongen GA (2021) Allopurinol to reduce cardiovascular morbidityand mortality: a systematic review and meta-analysis. PLoS One 16:e0260844","DOI":"10.1371\/journal.pone.0260844"},{"key":"7858_CR10","doi-asserted-by":"crossref","unstructured":"Lai SW, Liao KF, Kuo YH, Liu CS, Hwang BF (2022) Comparison of benzbromarone and allopurinol on primary prevention ofthe first gout flare in asymptomatic hyperuricemia. J Pers Med 12:697","DOI":"10.3390\/jpm12050697"},{"key":"7858_CR11","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1093\/rheumatology\/keae262","volume":"63","author":"EH Kang","year":"2024","unstructured":"Kang EH, Shin A, Park CS, Lee EB, Lee YJ, Curhan G (2024) Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study. Rheumatology 63:2433\u201341","journal-title":"Rheumatology"},{"key":"7858_CR12","doi-asserted-by":"crossref","unstructured":"Lai SW, Liao KF, Kuo YH, Lin CL, Liu CS, Hwang BF (2021) A head-to-head comparison of benzbromarone and allopurinol onthe risk of type 2 diabetes mellitus in people with asymptomatic hyperuricemia. Front Pharmacol 12:731370","DOI":"10.3389\/fphar.2021.731370"},{"key":"7858_CR13","doi-asserted-by":"crossref","unstructured":"Lai SW, Liao KF, Kuo YH, Hwang BF, Liu CS (2023) The risk of ischemic cerebrovascular disease associated withbenzbromarone use in gout people: a retrospective cohort study in Taiwan. Medicine (Baltimore) 102:e32779","DOI":"10.1097\/MD.0000000000032779"},{"key":"7858_CR14","doi-asserted-by":"crossref","unstructured":"Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d\u2019Avila R (2018) Xanthine oxidase inhibitors forprevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC CardiovascDisord 18:24","DOI":"10.1186\/s12872-018-0757-9"},{"key":"7858_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/jim-2018-000774","volume":"67","author":"SW Lai","year":"2019","unstructured":"Lai SW, Lin CL, Liao KF (2019) Case-control study examining the association between allopurinol use and ischemic cerebrovascular disease. J Invest Med 67:48\u201351","journal-title":"J Invest Med"},{"key":"7858_CR16","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1093\/eurheartj\/ehab619","volume":"42","author":"EH Kang","year":"2021","unstructured":"Kang EH, Park EH, Shin A, Song JS, Kim SC (2021) Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Eur Heart J 42:4578\u201388","journal-title":"Eur Heart J"},{"key":"7858_CR17","unstructured":"TriNetX. Real-world data. https:\/\/trinetx.com\/real-world-data\/. Accessed 1 Sept 2025"},{"key":"7858_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garc\u00eda-Erauskin G, Ruiz-Lucea E (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:545\u20139","journal-title":"Ann Rheum Dis"},{"key":"7858_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejim.2023.04.025","volume":"113","author":"SW Lai","year":"2023","unstructured":"Lai SW, Liao KF, Kuo YH, Hwang BF, Liu CS (2023) Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia. Eur J Intern Med 113:91\u20137","journal-title":"Eur J Intern Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07858-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:02:41Z","timestamp":1769763761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07858-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7858"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07858-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. This study is exempt from informed consent. The data reviewed is a secondary analysis of existing data, does not involve intervention or interaction with human subjects, and is de-identified per the de-identification standard defined in Section \u00a7164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section \u00a7164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert refreshed on December 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"The authors disclose that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}